The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, highlighting the need for longer, strengthened treatments.